amylin glp 1 dual agonist Amycretin — a novel obesity treatment that targets both GLP-1 and receptors — has shown early success in phase testing and will be advanced into phase 3 testing. http://ms.spr.ly/6185SLoJD 📢 Beyond GLP-1: The next

Estrogen and androgen balance Adipose tissue contains aromatase, an enzyme that converts androgens to estrogens

He has dedicated his career to helping patients find safe, effective, and sustainable solutions for obesity, including gastric sleeve, gastric bypass, revisional bariatric surgery, gastric balloon therapy, and medical weight loss

There were no bowel obstructions noted in the group taking Ozempic, but the study found a 0.8% incidence in people who were taking Saxenda, and a 0.17% incidence in people taking Contrave

Patients should contact their GP or diabetes specialist nurse if they experience unexpected changes in blood glucose control, significant gastrointestinal symptoms, or concerns about dietary modifications whilst on GLP-1 therapy

GLP-1RAs pose risks of severe eye complications, particularly worsening diabetic retinopathy with rapid and significant HbA1c reduction

D.et al (2021)